General Catalyst-backed Transcarent completed the acquisition of Accolade for $621m.

General Catalyst-backed Transcarent, a health and care experience company, completed the acquisition of Accolade, an innovative healthcare company, for $621m. “Transcarent and Accolade coming together is an important step to make it easier for everyone to access the high-quality, affordable health and care they deserve. WayFinding is already delivering faster and more personalized answers to critical health questions and easy access to care, when and where people need it, and always on their terms. Whether that's meeting virtually with their trusted primary care physician, instant connection to a Care Advocate, or getting care for complex needs like cancer treatment or surgery. Adding Accolade’s people and capabilities will significantly enhance our existing offerings. We’re creating an entirely new way to experience health and care. We are truly better together,” Glen Tullman, Transcarent CEO.